Close Menu

NEW YORK – Kevin Ness, the CEO of gene editing company Inscripta, has long had a vision of doing for genome writing what Illumina did for genome reading — to make genome engineering as innovative, as scalable, and as widespread as genome sequencing is today.

To do that, Inscripta has been developing an integrated suite of software, reagents, nucleases, and an automated benchtop instrument that are designed to work together in a way that seems to combine the principles behind CRISPR gene editing, single-cell genomics, and synthetic biology into one technological platform.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.